New Cannabis Ventures helped spearhead the Exclusive Public Companies Symposium at New West Summit in Oakland on October 13-14th. The goal of the event was to introduce leading public cannabis companies to investors interested in the sector. Among the 10 companies that presented were five Canadian licensed producers, including Aurora Cannabis (TSX: ACB) (OTC: ACBFF), Canopy Growth (TSX: WEED) (OTC: TWMJF), MedReleaf (TSX: LEAF) (OTC: MEDFF), Organigram (TSXV: OGI) (OTC: OGRMF) and The Green Organic Dutchman.
With the medical cannabis market growing rapidly and full legalization for adults on the horizon in Canada, the venue allowed the executives to share their growth strategies. Green Flower Media captured the presentations and Q&A, which we have included below along with a link to the slides.
Cam Battley, EVP at Aurora Cannabis, presented the company, describing its agility, innovation and execution and pointing to its production efficiency. He elaborated upon its original purpose-built facility and detailed the Aurora Sky and its Quebec facility, Aurora Vie. Battley discussed his optimism for the company’s prospects in Europe following its acquisition of distributor Pedanios.
Bruce Linton, CEO of Canopy Growth, presented the company as he discussed “Value Creation in a New Global Industry.” Linton described the overall global medical market as being as high as $180 billion and discussed the company’s brand strategy, its domestic expansion and its rapidly growing international footprint. He also detailed the backgrounds of the senior management team.
Igor Gimelshtein, CFO of MedReleaf, presented the company, which went public in June, detailing its five pillars, including quality assurance, patient-centric approach, data-driven operations, ongoing innovation and focus on premium cannabis. He pointed to the company’s near-term growth being boosted by a shift in sales towards oils and elaborated on its global footprint in Australia, Brazil and potentially Germany.
Greg Engel, CEO of Organigram, presented the company. Engel, who joined earlier this year after having previously headed Tilray, discussed the company’s strategic location, its brand positioning and strategic partnerships and the extensive experience of the management team. He shared guidance that the company, which is fully funded for its expansion, expects to produce 26mm grams in 2018.
The Green Organic Dutchman
Danny Brody, Director of Investor Relations at The Green Organic Dutchman, which is not yet a publicly-traded company, presented its story. The company is in the process of raising capital to fund its 970K sq. ft. expansion. Brody highlighted the company’s alliances, its organic methods of production, the management team, its land package and the financial team.